Modulators of resistant androgen receptor
US-9365542-B2 · Jun 14, 2016 · US
Modulators of resistant androgen receptor
US9650359B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9650359-B2 |
| Application number | US-201615158432-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 18, 2016 |
| Priority date | Oct 26, 2012 |
| Publication date | May 16, 2017 |
| Grant date | May 16, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides compounds useful as modulators, agonists or antagonists of androgen receptor (AR), compositions thereof, and methods of making and using the same.
First claim
Opening claim text (preview).
We claim: 1. A method of treating a cancer comprising administering to a patient in need thereof a compound represented by structural formula IV: or a pharmaceutically acceptable salt thereof, wherein: X is CH or N; each R b is independently substituted or unsubstituted C 1-6 aliphatic; and n is 0 to 4. 2. The method of claim 1 , wherein the cancer is a castration-resistant prostate cancer. 3. The method of claim 2 , wherein the castration-resistant prostate cancer bears one or more mutations in the androgen receptor. 4. The method of claim 3 , wherein the one or more mutations in the androgen receptor comprises a mutation of Phe876. 5. The method of claim 4 , wherein the mutation is Phe876 to Leu, Ile, Val, Ser, Cys, or Tyr. 6. The method of claim 4 , wherein the mutations further comprise one or more mutations to residues selected from the group consisting of E566, E589, E669, C687, A700, N772, H777, C785, F877, and K911. 7. The method of claim 2 , wherein the castration-resistant prostate cancer is resistant to Enzalutamide. 8. The method of claim 1 , wherein the compound is: 9. The method of claim 8 , wherein the compound is represented by the following structural formula: 10. The method of claim 8 , wherein the compound is represented by the following structural formula:
Assignees
Inventors
Classifications
condensed with carbocyclic rings or ring systems · CPC title
Oxygen and sulfur atoms, e.g. thiohydantoin · CPC title
- C07D401/04Primary
directly linked by a ring-member-to-ring-member bond · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9650359B2 cover?
- The present invention provides compounds useful as modulators, agonists or antagonists of androgen receptor (AR), compositions thereof, and methods of making and using the same.
- Who is the assignee on this patent?
- Memorial Sloan Kettering Cancer Center
- What technology area does this patent fall under?
- Primary CPC classification C07D401/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue May 16 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).